Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62b5c1c24a5a552ed105cbbee7789203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bcf4c523d208d2a3fd03bdc5fdd643c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
filingDate |
2011-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38f3bb63ec435222596995f80cba9a62 |
publicationDate |
2014-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014099714-A1 |
titleOfInvention |
Natural killer cell lines and methods of use |
abstract |
This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10960024-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017049208-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129850-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11752172-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058723-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758567-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018531229-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021154218-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11230699-B2 |
priorityDate |
1997-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |